Abstract
The availability of poly (ADP-ribose) polymerase (PARP) inhibitors for maintenance and treatment of advanced ovarian cancer has led to significant changes in the treatment paradigm for this disease. Upfront maintenance therapy with PARP inhibitors, with or without bevacizumab, is reducing recurrences which will hopefully translate to continued improvements in overall survival.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 54-57 |
| Number of pages | 4 |
| Journal | Journal of Managed Care Medicine |
| Volume | 26 |
| Issue number | 2 |
| State | Published - 2023 |
| Externally published | Yes |
ASJC Scopus subject areas
- Health Policy